MET and neoplasm: Several studies have reported that ALK or MET over-expression and constitutive kinase activation correlate with advanced stage and may be predictive of poor clinical outcome in several neoplasia, such as neuroblastoma, gastrointestinal carcinoma and non-small-cell lung cancer [19–23].